NASHVILLE, Tenn.--(BUSINESS WIRE)--

Insight Genetics, a molecular diagnostics company focused on advancing precision medicine in cancer care, announced today that it will present new data on triple-negative lung cancer at the American Association for Cancer Researchs (AACR) Annual Conference, which will be held at the Walter E. Washington Convention Center in Washington D.C. on April 6-10, 2013. The companys presentation will take place on April 8, 2013, from 1-5 p.m. in Hall A-C, Poster Section 32.

In a poster titled, The Unknown Piece of the Pie: Molecular Markers in Triple-Negative Lung Cancer, Insight Genetics scientists will highlight current research in evaluating the prevalence of the biomarker, DEPDC1, in non-small cell lung cancer (NSCLC) as a subset of triple-negative lung cancer, the cohort of lung cancers with the poorest prognosis.

Recent advancements in pulmonary oncology have linked the over-expression of DEPDC1 to extremely poor prognosis in a subset of triple-negative lung cancers not associated with mutations in EGFR, KRAS, and ALK. Using proprietary methods, Insight Genetics scientists have developed an assay to monitor the variants of DEPDC1, which could serve as a prognostic biomarker for this patient population.

The clinical results of this research may prove significant. Novel peptide vaccines against DEPDC1 antigens, which have been shown to be effective against bladder cancers, could potentially be extended to target the triple-negative lung cancer population.

Linking more cancers to specific biomarkers is one of the most promising new frontiers in oncology, said David Hout, Ph.D., Insight Genetics Vice President of Research and Development These findings have exciting diagnostic as well as therapeutic implicationsfor a subset of lung cancer patients, who today have limited treatment options and very poor prognoses.

About Insight Genetics

Insight Genetics is a molecular diagnostics company focused on enabling precision medicine in cancer therapy. The companys companion diagnostics detect specific cancer biomarkers related to therapeutics that are currently in development or on the market. Insight partners with leading academic researchers, pharmaceutical and biotechnology companies, clinical reference laboratories, and IVD kit manufacturers to provide new standards of care for cancer patients worldwide.www.insightgenetics.com

Read the original here:
Insight Genetics to Present Lung Cancer Findings at AACR 2013 Annual Meeting

Comments are closed.